Proving an increased acceptance of a novel group A meningococcal conjugate vaccine in Niger is a powerful advocacy tool that supports health care policymakers to expand mass vaccination campaigns. Therefore, a post-introduction evaluation plan to assess the impact of introducing the group A meningococcal conjugate vaccine in Niger is essential and will require substantial technical and financial contributions from our partners.

	Evaluation of the impact of the new conjugate vaccine introduction, including assessment of vaccine effectiveness.
	Strengthening case-based meningitis surveillance, before and after introduction of the new conjugate vaccine.